Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6507
    +0.0007 (+0.10%)
     

  • OIL

    82.88
    +0.07 (+0.08%)
     

  • GOLD

    2,324.80
    -13.60 (-0.58%)
     

  • Bitcoin AUD

    98,825.86
    -3,685.47 (-3.60%)
     

  • CMC Crypto 200

    1,385.69
    -38.41 (-2.70%)
     

  • AUD/EUR

    0.6075
    +0.0004 (+0.07%)
     

  • AUD/NZD

    1.0949
    +0.0007 (+0.06%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,295.93
    +94.66 (+0.55%)
     

  • NIKKEI 225

    37,675.23
    -784.85 (-2.04%)
     

Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022

Lumos Pharma, Inc.
·2-min read
Lumos Pharma, Inc.
Lumos Pharma, Inc.

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session following the prepared remarks.

Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing (833) 634-2295 (U.S.) or +1 (412) 902-4176 (international), or through the link, https://edge.media-server.com/mmc/p/ofen9o6f. The link to the live webcast may also be found in the “Investors & Media” section of the Lumos Pharma website, under “Events & Presentations.” A replay of the call will be available for two weeks from the date of the call and may be accessed through the same link above or by dialing (877) 344-7529 (U.S.) or +1 (412) 317-0088 (international) and using the passcode: 1602592.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.


Source: Lumos Pharma, Inc.

CONTACT: Investor & Media Contact: Lisa Miller Lumos Pharma Investor Relations 512-792-5454 ir@lumos-pharma.com